Mazdutide

A GLP-1 and glucagon receptor dual agonist studied largely in Chinese obesity and diabetes trials.

What research shows

Mazdutide has randomized trials spanning early phase through later studies, conducted largely in Chinese populations, showing weight loss and metabolic effects. Evidence outside that population is limited, and no marketing authorisation was found in the regulators covered on this page.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.